A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature

Go Nishikawa, Jia Luo, Vinay Prasad

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Importance: There is broad interest in patients who have exceptional responses to cancer drugs and only one prior systematic review of published case reports. Objective: To systematically summarise case reports of patients who have had a super response to a cancer drug and determine patterns and completeness of documentation. Design, setting and participants: This is a systematic search of biomedical literature and hand searches of seven prominent oncology journals. All cases were adults with cancer in the metastatic or unresectable setting and who were classified as having a remarkable response to a drug therapy were included. Our study was conducted between January 2017 and April 2017. Main outcomes and measures: We extracted patient and tumour characteristics, characteristics surrounding the exceptional response and pertinent oncologic history. Additionally, we noted authors’ financial conflicts of interest, if given. Results: We found 180 cases of exceptional response. The most common malignancy was breast cancer (28/180), and the most common class of drug therapy used was targeted therapies (161/274). The median year of publication was 2015. Depth of response included 33% (61/180) complete response, 55% (100/180) partial response and 7.7% (14/180) stable disease. The median length of response to the drug was 14 months. Fifty-nine percent (107/180) reported a driver mutation, and only 52% (56/107) reported two or more correlative studies. Only 14% (26/180) reported a denominator or total number treated to observe this response. Of cases that reported duration of response to a previous drug given in the unresectable setting, 49% demonstrated a progression-free survival ratio of exceptional response to prior line of 1.3 or greater (Von Hoff ratio). Conclusions and relevance: Our survey found that exceptional responders tended to have solid organ malignancies and most received targeted therapies. Many of our cases of exceptional responders were missing important information about the response and key oncologic history. Standardised criteria should be used to maximise usefulness of these case reports in the future.

LanguageEnglish (US)
Pages143-151
Number of pages9
JournalEuropean Journal of Cancer
Volume101
DOIs
StatePublished - Sep 1 2018

Fingerprint

Pharmaceutical Preparations
Neoplasms
History
Drug Therapy
Conflict of Interest
Documentation
Disease-Free Survival
Publications
Outcome Assessment (Health Care)
Breast Neoplasms
Mutation
Therapeutics
Surveys and Questionnaires

Keywords

  • Cancer outliers
  • Dramatic response
  • Exceptional responders
  • n of 1 medicine
  • Super responders

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. / Nishikawa, Go; Luo, Jia; Prasad, Vinay.

In: European Journal of Cancer, Vol. 101, 01.09.2018, p. 143-151.

Research output: Contribution to journalArticle

@article{b990f0993011451c9d29eec725890201,
title = "A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature",
abstract = "Importance: There is broad interest in patients who have exceptional responses to cancer drugs and only one prior systematic review of published case reports. Objective: To systematically summarise case reports of patients who have had a super response to a cancer drug and determine patterns and completeness of documentation. Design, setting and participants: This is a systematic search of biomedical literature and hand searches of seven prominent oncology journals. All cases were adults with cancer in the metastatic or unresectable setting and who were classified as having a remarkable response to a drug therapy were included. Our study was conducted between January 2017 and April 2017. Main outcomes and measures: We extracted patient and tumour characteristics, characteristics surrounding the exceptional response and pertinent oncologic history. Additionally, we noted authors’ financial conflicts of interest, if given. Results: We found 180 cases of exceptional response. The most common malignancy was breast cancer (28/180), and the most common class of drug therapy used was targeted therapies (161/274). The median year of publication was 2015. Depth of response included 33{\%} (61/180) complete response, 55{\%} (100/180) partial response and 7.7{\%} (14/180) stable disease. The median length of response to the drug was 14 months. Fifty-nine percent (107/180) reported a driver mutation, and only 52{\%} (56/107) reported two or more correlative studies. Only 14{\%} (26/180) reported a denominator or total number treated to observe this response. Of cases that reported duration of response to a previous drug given in the unresectable setting, 49{\%} demonstrated a progression-free survival ratio of exceptional response to prior line of 1.3 or greater (Von Hoff ratio). Conclusions and relevance: Our survey found that exceptional responders tended to have solid organ malignancies and most received targeted therapies. Many of our cases of exceptional responders were missing important information about the response and key oncologic history. Standardised criteria should be used to maximise usefulness of these case reports in the future.",
keywords = "Cancer outliers, Dramatic response, Exceptional responders, n of 1 medicine, Super responders",
author = "Go Nishikawa and Jia Luo and Vinay Prasad",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.ejca.2018.06.010",
language = "English (US)",
volume = "101",
pages = "143--151",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature

AU - Nishikawa, Go

AU - Luo, Jia

AU - Prasad, Vinay

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Importance: There is broad interest in patients who have exceptional responses to cancer drugs and only one prior systematic review of published case reports. Objective: To systematically summarise case reports of patients who have had a super response to a cancer drug and determine patterns and completeness of documentation. Design, setting and participants: This is a systematic search of biomedical literature and hand searches of seven prominent oncology journals. All cases were adults with cancer in the metastatic or unresectable setting and who were classified as having a remarkable response to a drug therapy were included. Our study was conducted between January 2017 and April 2017. Main outcomes and measures: We extracted patient and tumour characteristics, characteristics surrounding the exceptional response and pertinent oncologic history. Additionally, we noted authors’ financial conflicts of interest, if given. Results: We found 180 cases of exceptional response. The most common malignancy was breast cancer (28/180), and the most common class of drug therapy used was targeted therapies (161/274). The median year of publication was 2015. Depth of response included 33% (61/180) complete response, 55% (100/180) partial response and 7.7% (14/180) stable disease. The median length of response to the drug was 14 months. Fifty-nine percent (107/180) reported a driver mutation, and only 52% (56/107) reported two or more correlative studies. Only 14% (26/180) reported a denominator or total number treated to observe this response. Of cases that reported duration of response to a previous drug given in the unresectable setting, 49% demonstrated a progression-free survival ratio of exceptional response to prior line of 1.3 or greater (Von Hoff ratio). Conclusions and relevance: Our survey found that exceptional responders tended to have solid organ malignancies and most received targeted therapies. Many of our cases of exceptional responders were missing important information about the response and key oncologic history. Standardised criteria should be used to maximise usefulness of these case reports in the future.

AB - Importance: There is broad interest in patients who have exceptional responses to cancer drugs and only one prior systematic review of published case reports. Objective: To systematically summarise case reports of patients who have had a super response to a cancer drug and determine patterns and completeness of documentation. Design, setting and participants: This is a systematic search of biomedical literature and hand searches of seven prominent oncology journals. All cases were adults with cancer in the metastatic or unresectable setting and who were classified as having a remarkable response to a drug therapy were included. Our study was conducted between January 2017 and April 2017. Main outcomes and measures: We extracted patient and tumour characteristics, characteristics surrounding the exceptional response and pertinent oncologic history. Additionally, we noted authors’ financial conflicts of interest, if given. Results: We found 180 cases of exceptional response. The most common malignancy was breast cancer (28/180), and the most common class of drug therapy used was targeted therapies (161/274). The median year of publication was 2015. Depth of response included 33% (61/180) complete response, 55% (100/180) partial response and 7.7% (14/180) stable disease. The median length of response to the drug was 14 months. Fifty-nine percent (107/180) reported a driver mutation, and only 52% (56/107) reported two or more correlative studies. Only 14% (26/180) reported a denominator or total number treated to observe this response. Of cases that reported duration of response to a previous drug given in the unresectable setting, 49% demonstrated a progression-free survival ratio of exceptional response to prior line of 1.3 or greater (Von Hoff ratio). Conclusions and relevance: Our survey found that exceptional responders tended to have solid organ malignancies and most received targeted therapies. Many of our cases of exceptional responders were missing important information about the response and key oncologic history. Standardised criteria should be used to maximise usefulness of these case reports in the future.

KW - Cancer outliers

KW - Dramatic response

KW - Exceptional responders

KW - n of 1 medicine

KW - Super responders

UR - http://www.scopus.com/inward/record.url?scp=85050498407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050498407&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.06.010

DO - 10.1016/j.ejca.2018.06.010

M3 - Article

VL - 101

SP - 143

EP - 151

JO - European Journal of Cancer

T2 - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -